ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print

Drugmaker Shionogi inks deal to market COVID pill in China

Agreement with Sino Bio unit comes a month after antiviral drug's approval in Japan

Shionogi's Xocova is Japan's first locally developed oral treatment for COVID-19. (Nikkei montage)

TOKYO -- Japanese drugmaker Shionogi announced a partnership with a Chinese counterpart on Thursday to promote its oral COVID-19 treatment in China, as the country grapples with a surging outbreak.

The licensing agreement with Chia Tai Tianqing Pharmaceutical Group will let the Chinese company market the drug, known as Xocova, to medical institutions and pharmacies if it is approved by Chinese authorities.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more